PCSK9 and bladder transitional cell carcinoma: In bladder urothelial carcinoma (BLCA) (P < 0.01), kidney renal clear cell carcinoma (KIRC) (P < 0.05), kidney renal papillary cell carcinoma (KIRP) (P < 0.01), THCA (P < 0.001) and diffuse large B-cell lymphoma (DLBC) (P < 0.01), the results showed that PCSK9 expression was higher in stage IV&III tumors than in stage I&II tumors, while the opposite outcome was observed in UCEC (P < 0.01) (Figure S1B, Table S2).